New Delhi: The first nasal vaccine for swine
flu was launched in the capital on Tuesday.
Nasovac, manufactured by the Serum Institute, is a single
dose vaccine and is to be sniffed only once in each nostril.
Along with a needle prick-free benefit, Nasovac has a
superior efficacy profile based on its administration through
the respiratory route -- it mimics the path followed by the
virus to enter the body, Cyrus Poonawalla, Chairman, Serum
Institute of India Ltd said.
The safety and efficacy of the vaccine was established
through Clinical trials conducted in India for the vaccine.
With the outbreak of H1N1 infections in 2009, Serum
Institute in consultation with World Health Organisation (WHO)
and the Ministry of Health, Government of India started work
on the H1N1 vaccine. The company is already working on an
influenza vaccine under WHO guidance.